K
8.18
0.27 (3.41%)
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 混合的 |
| Biotechnology (全球的) | 混合的 | 混合的 | |
| 股票 | Kyverna Therapeutics, Inc. | 看涨 | 看涨 |
AIStockmoo 评分
0.5
| 分析师共识 | 5.0 |
| 内部交易活动 | NA |
| 价格波动 | -5.0 |
| 技术平均移动指标 | 0.0 |
| 技术振荡指标 | 2.0 |
| 平均 | 0.50 |
|
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 12.04% |
| 机构持股比例 | 68.57% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Vida Ventures Advisors, Llc | 30 Sep 2025 | 4,523,924 |
| Insight Holdings Group, Llc | 30 Sep 2025 | 989,054 |
| Mbb Public Markets I Llc | 30 Sep 2025 | 614,477 |
| 52周波幅 | ||
| 目标价格波幅 | ||
| 高 | 31.00 (Wells Fargo, 278.97%) | 购买 |
| 中 | 25.00 (205.62%) | |
| 低 | 20.00 (HC Wainwright & Co., 144.50%) | 购买 |
| 平均值 | 25.33 (209.66%) | |
| 总计 | 3 购买 | |
| 平均价格@调整类型 | 7.47 | |
| 公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
|---|---|---|---|---|
| Morgan Stanley | 04 Dec 2025 | 25.00 (205.62%) | 购买 | 7.84 |
| Wells Fargo | 30 Oct 2025 | 31.00 (278.97%) | 购买 | 6.75 |
| 08 Oct 2025 | 27.00 (230.07%) | 购买 | 7.18 | |
| HC Wainwright & Co. | 27 Oct 2025 | 20.00 (144.50%) | 购买 | 7.81 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合